Trials / Unknown
UnknownNCT02869815
ICG and Blue Dye Guided Sentinel Lymph Node Biopsy in Patients Underwent Neoadjuvant Therapy
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Using the Navigation of the Combination of Indocyanine and Blue Dye in Patients With Breast Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- Female
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The value of sentinel lymph node biopsy (SLNB) in patients underwent neoadjuvant chemotherapy is controversial. Lower detection rate and higher false negative rate are the main problem. The purpose of this study is to determine the detection rate and the false negative rate of SLNB by indocyanine green (ICG) in addition to blue dye (methylene blue) after neoadjuvant chemotherapy in patients with large or locally advanced breast cancer. This is a single arm clinical trial.
Detailed description
Patients indicated for neoadjuvant therapy would be recruited in this study. During the surgery, SLNB using the dual tracing method would be applied before axillary clearance. After the surgery, histological results of the SLN and non-SLN would be analysed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | ICG+Methylene Blue | ICG+Methylene Blue Arm: One ml of methylene blue (1%) would be in injected sub-areolarly 5 minutes before surgery, and 1ml of ICG (0.125%) in the same site 3 minutes later. Massage of the breast would be applied to facilitate the movement of the tracers. A small incision would be made in the axilla, and a special device would be used to search the light nodes. During the sampling, blue nodes would also be resected . After the completion of SLNB, complete axillary dissection would be carried out. |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2019-08-01
- Completion
- 2020-08-01
- First posted
- 2016-08-17
- Last updated
- 2019-05-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02869815. Inclusion in this directory is not an endorsement.